Major New Market Just Went Live! Time to See the Cash Flow

That little diagnostics company is making some big moves in Europe, and they just hit a major milestone.

They aren't messing around. Their main product, ColoAlert®, moved from regulatory approval (August 13, 2025) to a full-on commercial launch in Switzerland (September 23, 2025) in just a few weeks. That’s fast execution.

Why does this matter?

1. Real Revenue Now: This isn't just a future plan. It's a new market actively bringing in revenue for Mainz Biomed (MYNZ).
2. Smooth Operations: They already set up a local partnership with a lab in Switzerland. That means getting samples processed is quick and efficient. No logistics headaches, which helps doctors adopt the test quickly.

Keep an eye on any updates about this launch. If the volume of tests sold goes up quickly in Switzerland, it tells us good things about how their products will do in bigger markets like the U.K., where they also just got clearance.

MYNZ is a molecular diagnostics company focused on a better colon cancer screening test. With Germany already rolling out their test and Switzerland now live, are they about to prove that their European expansion is the real deal?